Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review

Journal of Medical Toxicology

Volumn 13, Issue 1, 2017, Pages 71-87

  Sorensen, Cecilia J ^a   DeSanto, Kristen ^b   Borgelt, Laura ^b   Phillips, Kristina T ^c   Monte, Andrew A ^a,d,e  

^a DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF NORTHERN COLORADO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

Author keywords

Cannabinoid hyperemesis syndrome; Cannabis; Cyclic vomiting syndrome; Marijuana

Indexed keywords

CANNABIS;

ABDOMINAL PAIN; CANNABINOID HYPEREMESIS SYNDROME; CANNABIS ADDICTION; CANNABIS USE; GENDER; HUMAN; NAUSEA AND VOMITING; ONSET AGE; REVIEW; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; VOMITING; CHEMICALLY INDUCED; COMPLICATION; DIFFERENTIAL DIAGNOSIS; META ANALYSIS; PATHOPHYSIOLOGY; SYNDROME;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MARIJUANA ABUSE; SYNDROME; VOMITING;

EID: 85006725080     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-016-0595-z     Document Type: Review

References (188)

1. United Nations Office on Drugs and Crime. World Drug Report [Internet]. 2014 [cited 26 November 2016] Available at: http://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf.
2. Results from the 2014 National Survey on Drug Use and Health: summary of national findings [Internet]. 2014 [cited 27 November 2016] Available at: http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf.
3. [No author listed] State marijuana laws in 2016. Governing the states and localities [Internet]. 2016 [cited 26 November 2016] Available at: http://www.governing.com/gov-data/state-marijuana-laws-map-medical-recreational.html.
4. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73.
5. Kim HS, Anderson JD, Saghafi O, Heard KJ, Monte AA. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med. 2015;22(6):694–9.
6. Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53(11):1566–70.
7. Perrotta G, Miller J, Stevens T, Chauhan A, Musunuru H, Salciccioli J, et al. Cannabinoid hyperemesis: relevance to emergency medicine. Acad Emerg Med. 2012;19:S286–S7.
8. Cox B, Chhabra A, Adler M, Simmons J, Randlett D. Cannabinoid hyperemesis syndrome: case report of a paradoxical reaction with heavy marijuana use. Case Rep Med. 2012;2012:757696.
9. Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012;87(2):114–9.
10. Wallace EA, Andrews SE, Garmany CL, Jelley MJ. Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. South Med J. 2011;104(9):659–64.
11. Patterson DA, Smith E, Monahan M, Medvecz A, Hagerty B, Krijger L, et al. Cannabinoid hyperemesis and compulsive bathing: a case series and paradoxical pathophysiological explanation. J Am Board Fam Med. 2010;23(6):790–3.
12. Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci. 2010;55(11):3113–9.
13. Sofka S, Lerfald N. Cannabinoid hyperemesis syndrome: a case series. W V Med J. 2013;109(3):20–3.
14. Masri KR, Moussa R, Licke H, El Haddad B. Chronic cannabis use with hyperemesis, epigastric pain and conditioned showering behavior. Journal of Gastroenterology and Hepatology Research. 2012;1(6):107–10.
15. Nicolson SE, Denysenko L, Mulcare JL, Vito JP, Chabon B. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. Psychosomatics. 2012;53(3):212–9.
16. Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid and hyperemesis. Mayo Clin Proc. 2012;87(5):503.
17. Achanta L, Kelkhoff AJ. Cannabinoid hyperemesis—is it more common than we think? J Ark Med Soc. 2013;109(8):158.
18. Alaniz VI, Liss J, Metz TD, Stickrath E. Cannabinoid hyperemesis syndrome: a cause of refractory nausea and vomiting in pregnancy. Obstet Gynecol. 2015;125(6):1484–6.
19. Bagdure S, Smalligan RD, Sharifi H, Khandheria B. Waning effect of compulsive bathing in cannabinoid hyperemesis. Am J Addict. 2012;21(2):184–5.
20. Baron M, Haymann JP, Wolfromm A, Rondeau E, Mesnard L. The smoker and the nephrologist cannabinoid hyperemesis syndrome. Kidney Int. 2011;79(12):1385–6.
21. Basaviah P, Liao C, Ramsey M. Hot water: cannabinoid hyperemesis. J Gen Intern Med. 2010;25:521.
22. Beech RA, Sterrett DR, Babiuk J, Fung H. Cannabinoid hyperemesis syndrome: a case report and literature review. J Oral Maxillofac Surg. 2015.
23. Bick BL, Szostek JH, Mangan TF. Synthetic cannabinoid leading to cannabinoid hyperemesis syndrome. Mayo Clin Proc. 2014;89(8):1168–9.
24. Bourke MG, McCormack O. Response to “desperate for a hot shower”. Ir Med J. 2014;107(8):258–9.
25. Braver O, Leibman Y. Cannabinoid hyperemesis syndrome: descriptive overview of an under-recognized diagnosis. Isr Med Assoc J. 2015;17(5):324–5.
26. Brenna O, Aasarod K, Gustafsson BI. A man in his 30s with recurrent vomiting and abdominal pain relieved by hot showers. Tidsskr Nor Laegeforen. 2011;131(21):2134–6.
27. Cha JM, Kozarek RA, Lin OS. Case of cannabinoid hyperemesis syndrome with long-term follow-up. World J Clin Cases. 2014;2(12):930–3.
28. Chen J, McCarron RM. Cannabinoid hyperemesis syndrome: a result of chronic, heavy cannabis use. Current Psychiatry. 2013;12(10):48–54.
29. Chepyala P, Olden KW. Cyclic vomiting and compulsive bathing with chronic cannabis abuse. Clin Gastroenterol Hepatol. 2008;6(6):710–2.
30. Cheung E, Ng C, Foote J. A hot mess: a case of hyperemesis. Can Fam Physician. 2014;60(7):633–7.
31. Desjardins N, Jamoulle O, Taddeo D, Stheneur C. Cannabinoid hyperemesis syndrome in a 17-year-old adolescent. J Adolesc Health. 2015.
32. Donnino MW, Cocchi MN, Miller J, Fisher J. Cannabinoid hyperemesis: a case series. J Emerg Med. 2011;40(4):e63–6.
33. Enuh HA, Chin J, Nfonoyim J. Cannabinoid hyperemesis syndrome with extreme hydrophilia. Int J Gen Med. 2013;6:685–7.
34. Figueroa-Rivera IM, Estremera-Marcial R, Sierra-Mercado M, Gutierrez-Nunez J, Toro DH. Cannabinoid hyperemesis syndrome: a paradoxical cannabis effect. Case Rep Gastrointest Med. 2015;2015:405238.
35. Fleig S, Brunkhorst R. Hyperemesis and a high water bill. Z Gastroenterol. 2011;49(11):1479–81.
36. Gessford AK, John M, Nicholson B, Trout R. Marijuana induced hyperemesis: a case report. W V Med J. 2012;108(6):20–2.
37. Gupta N, Ojo O, Muruthettuwegama K. Cannabinoid hyper-emesis syndrome: an enigma. Indian J Psychol Med. 2013;35(4):405–6.
38. Habboushe J, Sedor J. Cannabinoid hyperemesis acute renal failure: a common sequela of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2014;32(6):690.e1–2.
39. Heise L. Cannabinoid hyperemesis syndrome. Adv Emerg Nurs J. 2015;37(2):95–101.
40. Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2013;31(6):1003.e5–6.
41. Hopkins CY, Gilchrist BLA. Case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med. 2013;45(4):544–6.
42. Shaq S, Ismail S, Ghaus S, Roop EZ, Rostami K. Cannabinoid hyperemesis should be recognised as an effect of chronic cannabis abuse. Gastroenterol Hepatol Bed Bench. 2014;7(3):173–6.
43. Khayambashi S. Unusual cause of nausea, vomiting and abdominal pain. J Gen Intern Med. 2012;27:S497–S8.
44. Krishnan SK, Khaira H, Ganipisetti VM. Cannabinoid hyperemesis syndrome: truly an oxymoron. J Gen Intern Med. 2014;29:S328.
45. Acopetti CL, Packer CD. Cannabinoid hyperemesis syndrome: a case report and review of pathophysiology. Clin Med Res. 2014;12(1–2):65–7.
46. Luther V, Yap L. A hot bath to calm what ails you: the cannabis hyperemesis syndrome. Acute Med. 2012;11(1):23–4.
47. Mahmad AI, Jehangir W, Littlefield JM, John S, Yousif A. Cannabis hyperemesis syndrome: a case report review of treatment. Toxicology Reports. 2015;2:889–90.
48. Mattens V, Aerts M, Mana F, Urbain D. Daily cannabis use and the digestive tract: an underrecognized relationship. Acta Gastroenterol Belg. 2010;73(3):403–5.
49. Miller JB, Walsh M, Patel PA, Rogan M, Arnold C, Maloney M, et al. Pediatric cannabinoid hyperemesis: two cases. Pediatr Emerg Care. 2010;26(12):919–20.
50. Mohammed F, Panchoo K, Bartholemew M, Maharaj D. Compulsive showering and marijuana use—the cannabis hyperemesis syndrome. Am J Case Rep. 2013;14:326–8.
51. Morris R, Fisher M. Cannabinoid hyperemesis syndrome: a specific cause of cyclical vomiting. Int J Adolesc Med Health. 2014;26(1):153–6.
52. Nogi M, Fergusson D, Chiaco JM. Mid-ventricular variant takotsubo cardiomyopathy associated with cannabinoid hyperemesis syndrome: a case report. Hawaii J Med Public Health. 2014;73(4):115–8.
53. Nour SA, Nour HA, Byrd R, Mehta J, Roy T. Bath time: an unusual etiology for hypovolemic shock in a young patient. Crit Care Med. 2012;40(12):289.
54. Oruganti VV, Ward LD. Mid-Atlantic regional resident award winner: reverse munchies: a case of cannabinoid hyperemesis. J Gen Intern Med. 2009;24:378–9.
55. Pandey TS, Salim T. Clinical vingnettes “I am always in the hot shower.” cannabinoid hyperemesis syndrome—a case report. J Gen Intern Med. 2014;29:S262.
56. Parikh M, Gould M. Cyclical vomiting syndrome: is pot really at the bottom of the pot? Am J Gastroenterol. 2010;105:S363.
57. Price SL, Fisher C, Kumar R, Hilgerson A. Cannabinoid hyperemesis syndrome as the underlying cause of intractable nausea and vomiting. J Am Osteopath Assoc. 2011;111(3):166–9.
58. Raja MW, Patel D, Chemitiganti R, Burks JK. Cannabinoid hyperemesis syndrome: a consideration in patients with refractory emesis. J Investig Med. 2012;60(1):313–4.
59. Rashid S, Dahl K, Moise D, Subramani K, Rizvon K, Mustacchia P. Cannabinoid hyperemesis syndrome—an obscure clinical diagnosis. Am J Gastroenterol. 2009;104:S366.
60. Robinson TL, Cheng FK, Domingo CA, Kim CH, Ally MT, Itzkowitz SL. Spicing up the differential for cyclical vomiting. Am J Gastroenterol. 2013;108(8):1371.
61. Roche E, Foster PN. Cannabinoid hyperemesis: not just a problem in Adelaide Hills. Gut. 2005;54(5):731.
62. Roca-Pallin JM, Lopez-Pelayo H, Sugranyes G, Balcells-Olivero MM. Cannabinoid hyperemesis syndrome. CNS Neurosci Ther. 2013;19(12):994–5.
63. Sannarangappa V, Tan C. Cannabinoid hyperemesis. Intern Med J. 2009;39(11):777–8.
64. Schmid SM, Lapaire O, Huang DJ, Jurgens FE, Guth U. Cannabinoid hyperemesis syndrome: an underreported entity causing nausea and vomiting of pregnancy. Arch Gynecol Obstet. 2011;284(5):1095–7.
65. Sharma AN, Hoffman RJ. Cyclical hyperemesis associated with frequent marijuana use: a case report. Clin Toxicol. 2008;46(5):394.
66. Wild K, Wilson H. Cannabinoid hyperemesis. BMJ Case Rep. 2010.
67. Williamson JE, July M, Gonzalez LM, Amin HH, Chaudhari S. Cannabinoid hyperemesis syndrome: cyclical vomiting behind the cloud of smoke. Am J Med. 2014;127(4):e1–2.
68. Woods JA, Wright NJ, Gee J, Scobey MW. Cannabinoid hyperemesis syndrome: an emerging drug-induced disease. Am J Ther. 2014.
69. Boeckxstaens GE. Cannabinoid hyperemesis with the unusual symptom of compulsive bathing. Ned Tijdschr Geneeskd. 2005;149(26):1468–71.
70. Alfonso Moreno V, Ojesa F, Moreno-Osset E. Cannabinoid hyperemesis. Gastroenterol Hepatol. 2006;29(7):434–5.
71. Wallace D, Martin AL, Park B. Cannabinoid hyperemesis: marijuana puts patients in hot water. Australas Psychiatry. 2007;15(2):156–8.
72. Chang YH, Windish DM. Cannabinoid hyperemesis relieved by compulsive bathing. Mayo Clin Proc. 2009;84(1):76–8.
73. Ochoa-Mangado E, Jimenez Gimenez M, Salvador Vadillo E, Madoz-Gurpide A. Cyclical hyperemesis secondary to cannabis abuse. Gastroenterol Hepatol. 2009;32(6):406–9.
74. Watts M. Cannabinoid hyperemesis presenting to a New Zealand hospital. N Z Med J. 2009;122(1290):116–8.
75. Budhraja V. Confirming the diagnosis of cannabinoid hyperemesis. Mayo Clin Proc. 2009;84(5):483. author reply
76. Carhill A, Wiese J. Your stomach on drugs: cyclic vomiting in association with chronic cannabis abuse. J Gen Intern Med. 2007;22:255.
77. Cheng FK, Robinson T, Domingo C, Ally M, Kim CH, Itzkowitz S. Spicing up the differential for cyclic vomiting: a case of synthetic-cannabinoid induced hyperemesis syndrome. Am J Gastroenterol. 2012;107:S268–S9.
78. Estremera R, Figueroa I, Sierra M, Toro DA. paradoxical cannabis effect. Am J Gastroenterol. 2014;109:S54.
79. Muschart X, Flament J. A non-classical cannabinoid syndrome. Acta Clin Belg. 2015;70(4):299–300.
80. Ramos S, Rodrigues R, Almeida N, Sa JM, Fonseca L. Cannabinoid hyperemesis syndrome. Psychother Psychosom. 2013;82:90.
81. Sadiq M. Cannabis hyperemesis syndrome. Journal of Addiction Medicine. 2013;7(4):E3.
82. Shah S, Gilbert C, Toth J, Reed M. Cannabinoid hyperemesis syndrome causing pneumomediastinum and pneumorachis. Chest. 2014;146(4).
83. Atkins D. Grading quality of evidence and strength of recommendations. Brit Med Jou. 2004;328(7454):1490.
84. Abalo R, Cabezos PA, Vera G, Lopez-Perez AE, Martin MI. Cannabinoids may worsen gastric dysmotility induced by chronic cisplatin in the rat. Neurogastroenterol Motil. 2013;25(5):373–82. e292
85. Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol. 2002;137(5):589–96.
86. Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol. 2009;156(1):153–62.
87. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos. 1995;23(8):825–31.
88. Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav. 2001;69(1–2):239–49.
89. Darmani NA. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther. 2002;300(1):34–42.
90. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9.
91. Fennessy MR, Taylor DA. The effect of delta9-tetrahydrocannabinol on body temperature and brain amine concentrations in the rat at different ambient temperatures. Br J Pharmacol. 1977;60(1):65–71.
92. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol. 1999;384(1):37–42.
93. Izzo AA, Mascolo N, Capasso R, Germano MP, De Pasquale R, Capasso F. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedeberg’s Arch Pharmacol. 1999;360(2):221–3.
94. Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science. 1973;179(4071):391–3.
95. Krowicki ZK, Moerschbaecher JM, Winsauer PJ, Digavalli SV, et al. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol. 1999;371(2–3):187–96.
96. Kwiatkowska M, Parker LA, Burton P, Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology. 2004;174(2):254–9.
97. Lichtman AH, Wiley JL, LaVecchia KL, Neviaser ST, et al. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. Eur J Pharmacol. 1998;357(2–3):139–48.
98. Lundberg DJ, Daniel AR, Thayer SA. Delta(9)-tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture. Neuropharmacology. 2005;49(8):1170–7.
99. Moldrich G, Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides. 2000;21(11):1735–42.
100. Rawls SM, Cabassa J, Geller EB, Adler MW. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrr olo[3,2,1ij]quinolin-6-one)]-induced hypothermia. J Pharmacol Exp Ther. 2002;301(3):963–8.
101. Rock EM, Goodwin JM, Limebeer CL, Breuer A, Pertwee RG, Mechoulam R, et al. Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology. 2011;215(3):505–12.
102. Ros J, Claria J, To-Figueras J, Planaguma A, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology. 2002;122(1):85–93.
103. Schulze DR, Carroll FI, McMahon LR. Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys. Psychopharmacology. 2012;222(3):425–38.
104. Smirnov MS, Kiyatkin EA. Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats. Brain Res. 2008;1228:145–60.
105. Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res. 2006;45(5):405–46.
106. Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA. Distribution of the cannabinoid 1 receptor in the brainstem and gut: a novel neuroregulatory system in emesis. Gastroenterology. 2001;120(5):A197.
107. Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Lichtman AH. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther. 2005;314(1):329–37.
108. Fabries P, Ribaud N, Puidupin A, Coton T. Cannabinoid hyperemesis syndrome. Presse Medicale. 2013;42(11):1531–3.
109. Felton D, Zitomersky N, Manzi S, Lightdale JR. 13-year-old girl with recurrent, episodic, persistent vomiting: out of the pot and into the fire. Pediatrics. 2015;135(4):e1060–3.
110. Gremida A, Gammack J. Marijuana-induced cyclic vomiting: what clinicians need to know. Am J Gastroenterol. 2014;109:S544.
111. Harris E, McDonagh M, Kennedy N. Cannabis and hyperemesis. Ir J Psychol Med. 2010;27(1):47–8.
112. Kraemer RR, La Hoz RM, Willig JH. Some like it hot: erythema ab igne due to cannabinoid hyperemesis. J Gen Intern Med. 2013;28(11):1522.
113. Lemaire N, Douillart C, Deheul S, Bordet R, Gautier S. Cannabis-induced hyperemesis: unusual symptoms associated with chronic cannabis abuse. Fundamental & Clinical Pharmacology. 2010;24:96–7.
114. Louie RK, Lee JC. Psychiatric interventions for cannabinoid-induced hyperemesis syndrome in a diabetic patient. Am J Addict. 2015;24(1):59–60.
115. Qipo A, DeLorme J, Anis K, Acharya A, Ansari N. Cannabinoid hyperemesis syndrome (CHS) versus uremia in a patient with end stage renal disease. Am J Kidney Dis. 2014;63(5):A92.
116. Shinha T, Agarwal R, Lazarides A, Levey R. Cannabinoid-induced gastroparesis. Am J Gastroenterol. 2011;106:S189–S90.
117. Velasco A, Pentecost P. An unexpected etiology of cyclical vomiting. J Hosp Med. 2012;7:S281.
118. Vujasinović M, Ivartnik M, Tretjak M. Cannabinoid hyperemesis syndrome—case report. Zdravniski Vestnik. 2012;81(2):159–62.
119. Sontineni SP, Chaudhary S, Sontineni V, Lanspa SJ. Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse. World J Gastroenterol. 2009;15(10):1264–6.
120. Sun S, Zimmermann AE. Cannabinoid hyperemesis syndrome. Hosp Pharm. 2013;48(8):650–5.
121. Pattathan MB, Hejazi RA, McCallum RW. Association of marijuana use and cyclic vomiting syndrome. Pharmaceuticals (Basel). 2012;5(7):719–26.
122. Darmani NA. Cannabinoid-induced hyperemesis: a conundrum—from clinical recognition to basic science mechanisms. Pharmaceuticals. 2010;3(7):2163–77.
123. Hasenoehrl C, Taschler U, Storr M, Schicho R. The gastrointestinal tract—a central organ of cannabinoid signaling in health and disease. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society. 2016.
124. Lee Y, Jo J, Chung HY, Pothoulakis C, Im E. Endocannabinoids in the gastrointestinal tract. American journal of physiology Gastrointestinal and liver physiology. 2016;311(4):G655–G66.
125. Watkins BA, Kim J. The endocannabinoid system: directing eating behavior and macronutrient metabolism. Front Psychol. 2014;5:1506.
126. Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol. 2014;722:134–46.
127. McCoy KL. Interaction between cannabinoid system and toll-like receptors controls inflammation. Mediat Inflamm. 2016;2016:5831315.
128. Rubino T, Zamberletti E, Parolaro D. Endocannabinoids and mental disorders. Handb Exp Pharmacol. 2015;231:261–83.
129. Prospero-Garcia O, Amancio-Belmont O, Becerril Melendez AL, Ruiz-Contreras AE, Mendez-Diaz M. Endocannabinoids and sleep. Neuroscience and biobehavioral reviews. 2016.
130. Malek N, Starowicz K. Dual-acting compounds targeting endocannabinoid and endovanilloid systems—a novel treatment option for chronic pain management. Front Pharmacol. 2016;7:257.
131. Del Mar Ramirez Fernandez M, De Boeck G, Wood M, Lopez-Rivadulla M, Samyn N. Simultaneous analysis of THC and its metabolites in blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;875(2):465–70.
132. McCallum R, Soykan I. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmaco Ther. 1999;13(1):77–80.
133. Abalo R, Vera G, Lopez-Perez AE, Martinez-Villaluenga M, Martin-Fontelles MI. The gastrointestinal pharmacology of cannabinoids: focus on motility. Pharmacology. 2012;90(1–2):1–10.
134. Al-Mahdawi R, McMann LJ, Alwardi T, Naseer M, Sabbagh H, Kulairi Z. Marijuana induced biliary dyskinesia. J Gen Intern Med. 2015;30:S325–S6.
135. Crowley TJ, MacDonald MJ. Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend. 1998;50(1):27–37.
136. Sim LJ, Hampson RE, Deadwyler SA, Childers SR. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci. 1996;16(24):8057–66.
137. Parfieniuk A, Flisiak R. Role of cannabinoids in chronic liver diseases. World J Gastroenterol. 2008;14(40):6109–14.
138. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999;83(4):637–49.
139. Aviello G, Romano B, Izzo AA. Cannabinoids and gastrointestinal motility: animal and human studies. Eur Rev Med Pharmacol Sci. 2008;12(Suppl 1):81–93.
140. Bashashati M, McCallum RW. Neurochemical mechanisms and pharmacologic strategies in managing nausea and vomiting related to cyclic vomiting syndrome and other gastrointestinal disorders. Eur J Pharmacol. 2014;722(1):79–94.
141. Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav. 2008;93(4–5):666–70.
142. Coutts AA. Cannabinoid receptor activation and the endocannabinoid system in the gastrointestinal tract. Curr Neuropharmacol. 2004;2(1):91–102.
143. Coutts AA, Izzo AA. The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol. 2004;4(6):572–9.
144. Darmani NA, Sim-Selley LJ, Martin BR, Janoyan JJ, Crim JL, Parekh B, et al. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. Eur J Pharmacol. 2003;459(1):83–95.
145. Darmani NA. Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions. Methods Mol Med. 2006;123:169–89.
146. Fioramonti J, Bueno L. Role of cannabinoid receptors in the control of gastrointestinal motility and perception. Expert Review of Gastroenterology and Hepatology. 2008;2(3):385–97.
147. Inui A. Emesis, appetite, and endocannabinoids. Gastroenterology. 2002;123(2):655–6.
148. Izzo AA, Mascolo N, Capasso F. Cannabis and cannabinoid receptors—Third Monothematic Meeting of the Italian Society of Pharmacology, Naples, May 2000: Guest editorial. Pharm Pharmacol Commun. 2000;6(6):229.
149. Izzo AA, Coutts AA. Cannabinoids and the digestive tract. Handb Exp Pharmacol. 2005(168):573–98.
150. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 2008;57(8):1140–55.
151. Lin XH, Wang YQ, Wang HC, Ren XQ, Li YY. Role of endogenous cannabinoid system in the gut. Sheng Li Xue Bao. 2013;65(4):451–60.
152. ML L, Agito MD. Cannabinoid hyperemesis syndrome: marijuana is both antiemetic and proemetic. Cleve Clin J Med. 2015;82(7):429–34.
153. Malik Z, Baik D, Schey R. The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr Gastroenterol Rep. 2015;17(2):429.
154. Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol. 2004;2(4):305–14. discussion 14-6
155. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med. 2005;83(12):944–54.
156. Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 2011;163(7):1411–22.
157. Sanger GJ. Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol. 2007;152(5):663–70.
158. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol. 2003;15(2):91–119.
159. Tache Y. Cyclic vomiting syndrome: the corticotropin-releasing-factor hypothesis. Dig Dis Sci. 1999;44(8 Suppl):79s–86s.
160. Traver F, Edo S, Haro G. Cyclic hyperemesis secondary to chronic consumption of cannabis: a reconceptualization of psychogenic vomiting. Addictive Disorders and their Treatment. 2009;8(4):175–84.
161. Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer. 2011;19(6):843–51.
162. de Moore GM. Value of the single case report. Marijuana, vomiting and compulsive bathing: a new clinical syndrome? Aust N Z J Psychiatry. 2005;39(11–12):1046.
163. Janczyk P, Donaldson CW, Gwaltney S. Two hundred and thirteen cases of marijuana toxicoses in dogs. Vet Hum Toxicol. 2004;46(1):19–21.
164. Praharaj SK, Sarkhel S. Rimonabant-induced persistent vomiting. German Journal of Psychiatry. 2013;16(1):49–50.
165. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol. 2007;7(6):575–82.
166. Caplow J, Aizenberg DJ. New on the differential for kidney failure: cannabinoid hyperemesis syndrome. J Gen Intern Med. 2015;30:S431.
167. Witsil JC, Hickey JL, Mycyk MB. Haloperidol successfully treats cannabinoid hyperemesis syndrome. Clin Toxicol. 2013;51(7):591.
168. Lapoint J. Case series of patients treated for cannabinoid hyperemesis syndrome with capsaicin cream. Clin Toxicol. 2014;52(7):707.
169. Biary R, Oh A, Lapoint J, Nelson LS, Hoffman RS, Howland MA. Topical capsaicin cream used as a therapy for cannabinoid hyperemesis syndrome. Clin Toxicol. 2014;52(7):787.
170. Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011;4(4):241–9.
171. Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SKF, Fleisher DR, et al. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008;20(4):269–84.
172. Aljomah G, Hutchings R. Cyclic vomiting syndrome (CVS): a management challenge across the ages. Am J Gastroenterol 2011;106:S401.
173. Choung RS, Locke GR 3rd, Lee RM, Schleck CD, Zinsmeister AR, Talley NJ. Cyclic vomiting syndrome and functional vomiting in adults: association with cannabinoid use in males. Neurogastroenterol Motil 2012;24(1):20–26, e1.
174. Guidelines--Rome III. Diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):307–12.
175. Fajardo NR, Cremonini F, Talley NJ. Cyclic vomiting syndrome and chronic cannabis use. Am J Gastroenterol. 2005;100(9):S343.
176. Hejazi RA, McCallum RW. Review article: cyclic vomiting syndrome in adults—rediscovering and redefining an old entity. Aliment Pharmacol Ther. 2011;34(3):263–73.
177. Namin F, Patel J, Lin Z, Sarosiek I, Foran P, Esmaeili P, et al. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. Neurogastroenterol Motil. 2007;19(3):196–202.
178. Oruganti V, Sachdeva P, Fisher RS, Parkman HP. Cyclic vomiting syndrome in adults: relationship to cannabis use, migraine headaches, and intervening symptoms. Gastroenterology. 2010;138(5):S380.
179. Venkatesan T, Samuel EA, Kumar N, Sengupta J, Ali M, Faddis M, et al. The endocannabinoid system (ECS) and the hypothalamic-pituitary-adrenal (HPA) axis in adults with cyclic vomiting syndrome (CVS). Gastroenterology. 2013;144(5):S924.
180. Manning L, Eckford S. Cannabinoid hyperemesis syndrome in pregnancy. Bjog-an International J Obstet Gynaecol. 2012;119:27.
181. Andrews KH, Bracero LA. Cannabinoid hyperemesis syndrome during pregnancy: a case report. J Reprod Med. 2015;60(9–10):430–2.
182. Ukaigwe A, Karmacharya P, Donato AA. Gut gone to pot: a case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med. 2014;2014:1670–98.
183. Hejazi RA, Lavenbarg TH, Foran P, McCallum RW. Who are the nonresponders to standard treatment with tricyclic antidepressant agents for cyclic vomiting syndrome in adults? Aliment Pharmacol Ther. 2010;31(2):295–301.
184. Martinez AMC, Singh E. Marijuana: anti-emetic or pro-emetic? Am J Gastroenterol. 2012;107:S281.
185. Darmani NA. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001;430(1):49–58.
186. Turner CE, Elsohly MA, Boeren EG. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod. 1980;43(2):169–234.
187. Hejazi R, Lavenbarg TH, Foran P, McCallum RW. Who are the non-responders to standard therapy for cyclic vomiting syndrome in adults? A large single center experience. Neurogastroenterol Motil. 2009;21:65.
188. Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16(12):2324–37.